Connect Biopharma Holdings Ltd (CNTB) - Total Liabilities
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has total liabilities worth $17.44 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Connect Biopharma Holdings Ltd - Total Liabilities Trend (2018–2025)
This chart illustrates how Connect Biopharma Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. See Connect Biopharma Holdings Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Connect Biopharma Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Amir Marketing and Investments in Agriculture Ltd
TA:AMRK
|
Israel | ILA556.14 Million |
|
Midnight Sun Mining Corp
V:MMA
|
Canada | CA$678.98K |
|
Hardwyn India Limited
NSE:HARDWYN
|
India | Rs756.38 Million |
|
CB Industrial Product Holding
KLSE:7076
|
Malaysia | RM217.44 Million |
|
GREENLAND RESOURCES INC.
F:M0LY
|
Germany | €548.91K |
|
Tharimmune Inc.
NASDAQ:THAR
|
USA | $121.22 Million |
|
Avatec Co. Ltd
KQ:149950
|
Korea | ₩10.91 Billion |
|
Bastogi S.p.A
F:BAOA
|
Germany | €190.94 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Connect Biopharma Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CNTB company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Connect Biopharma Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual total liabilities of Connect Biopharma Holdings Ltd from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.10 Million | +54.58% |
| 2024-12-31 | $9.12 Million | -64.77% |
| 2023-12-31 | $25.88 Million | +56.64% |
| 2022-12-31 | $16.52 Million | -12.10% |
| 2021-12-31 | $18.80 Million | -62.01% |
| 2020-12-31 | $49.47 Million | +255.63% |
| 2019-12-31 | $13.91 Million | -84.32% |
| 2018-12-31 | $88.70 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.